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OBJECTIVES: Donabedian described client satisfaction as “the
ultimate validator” of quality in health care. Identify items in the
Medicare Current Beneﬁciary Survey (MCBS)—-2002 as mea-
sured by satisfaction regarding health care access that correlate
with satisfaction with quality of care. This is the ﬁrst step in
developing a new model that relates health care access to health
care quality as measured by consumer/patient satisfaction.
METHODS: Access items from the survey were measured by a
4-point satisfaction scale: 1 = very satisﬁed to 4 = very dissatis-
ﬁed. Only responses on the 1 to 4 scale were used; all other
responses or non-responses were considered as missing data. The
missing data then were imputed employing the EM algorithm;
complete cases were used in the analysis (N = 16,087). A linear
regression model by weighted least squares using the one-year
cross-sectional weights from the MCBS is done using items in
the survey, measured by satisfaction, that correspond to Pen-
chansky and Thomas’ ﬁve dimensions of health care access-
accessibility, acceptability, accommodation, affordability, and
availability- and are regressed on the dependent variable
MCQUALTY (satisfaction with medical care received in last
year). RESULTS: The regression model identiﬁed sixteen of 20
eligible items that signiﬁcantly correlated (p < 0.05) to satisfac-
tion with quality of care in the Medicare population of 2002.
CONCLUSIONS: Health care access and quality of care as mea-
sured by satisfaction have signiﬁcant correlation in the Medicare
population.
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The Saudi Arabian Ministry of Health (MOH) controls the uti-
lization of the free pharmacy beneﬁt program (PBP) by having a
closed universal formulary and ensures the effectiveness of the
PBP by instituting a pharmacy & therapeutics (P&T) committee
in each hospital. OBJECTIVES: To test the relationship among
the levels of development P&T committees and patients’ access
rates to prescription drugs. METHODS: A cross-sectional
descriptive survey design was conducted in the ﬁrst phase and
covered 127 MOH pharmacy managers at non-specialized hos-
pitals. The survey gathered information about: hospital, phar-
macy, and P&T committee characteristics. The survey results
were used to classify the MOH hospitals according to the levels
of development of the P&T committee. In the second phase, the
prescription audit phase, hospitals deliberately were selected
based on the hospitals’ P&T committee levels of development.
From each hospital, 150 patient records were systematically
sampled and patient’s access rate was calculated for each patient.
Analysis of variance (ANOVA) was used to test the existence of
a signiﬁcant difference in the access rates across the levels of
development of P&T committee. RESULTS: Of 127 MOH hos-
pitals, 81 (63.7%) hospitals were valid for the analysis. Of 81
hospitals, 13, 24, 39, 5 hospitals have undeveloped, poorly, par-
tially, and developed P&T committees, respectively. A total of
6885 prescription drugs were prescribed for 2850 patients in 19
audited hospitals. The overall rate for patients’ access was
97.3%. The ANOVA tests for the existence of a signiﬁcant dif-
ference of access rates across the levels of development of P&T
committee showed mixed results. CONCLUSIONS: The positive
relationship between the levels of development of P&T commit-
tee and patient’s access to prescription drugs was not conclusive.
However, the ﬁnding might be due to lack of enough data and
controls of other confounding variables rather than inexistence
of the relationship.
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OBJECTIVES: A newly developed 90-day retail-dispensing
program allows members to obtain 90-day supplies of mainte-
nance medications through a retail pharmacy stores at a discount
co-payment. The objective of this study is to investigate if there
is any relationship between generic utilization observed in pre-
scriptions dispensed through this channel and members’ co-pay
difference between brand and generic medications. METHODS:
The analysis was conducted using pharmacy claim data obtained
from a pharmacy beneﬁt management organization. Clients
included in the analysis were those who implemented the 90-day
retail program from January 2004 to July 2004 and also allowed
its members to obtain prescriptions through both 90-day mail
and 30-day retail channels. The relationship between generic uti-
lization and co-pay structure was assessed using multiple regres-
sion analysis. The dependent variable was proportion of generic
prescription claims dispensed through 90-day retail channel. The
independent variables were ratio of brand to generic cost, the
absolute co-pay amount difference between brand and generic
medications, age, gender, and prior generic utilization of 90-day
mail as well as 30-day retail program. RESULTS: A total of 25
clients were included in the analysis. In 90-day retail program,
the generic utilization ranged from 21.5% to 77.5%, ratio of
brand to generic cost varied from 1.9 to 6.2, and absolute co-
pay amount difference between brand and generic medications
varied from $11.2 to $101.5. A linear, positive relationship was
observed between generic utilization and ratio of brand to
generic cost (P < 0.05). Previous 90-day mail generic utilization
was also found to have positive impact on the 90-day retail
generic utilization (P < 0.05). CONCLUSIONS: Study results
indicate an increase in co-pay difference between brand and
generic medications do have a positive impact on 90-day retail
generic utilization. Further investigation is needed to test the
relationship between co-pay structure and generic utilization
among different channels.
PHP18
IMPACT OF STEPS (SAFE,THERAPEUTIC AND ECONOMIC
PHARMACEUTICAL SELECTION) MODEL ON PRESCRIBING
COSTS OF STATINS
Alabbadi I1, Crealey G2,Troughton T3, Baird S4, Miars J5, Scott M3,
McElnay J1
1Queen’s University Belfast, Belfast, UK, 2Clinical Research Support
Centre & Queen’s University Belfast, Belfast, UK, 3Antrim Area
Hospital, Antrim, UK, 4Broughshane Medical Practice, Antrim, UK,
5United Hospitals Trust, Antrim, UK
OBJECTIVE: STEPS is a structured model for the selection of
drugs for formulary inclusion. The aim of this study was to use
the STEPS model in the selection of statin products for use within
a health board in Northern Ireland. METHODS: The STEPS
model involved three phases in sequence: an evidence based
pharmacotherapeutic evaluation of all available statin drug enti-
ties in the UK, a separate safety/risk assessment analysis of
product lines of drug entities which exceeded the pharma-
cotherapeutic threshold and ﬁnally a budget impact analysis. A
